Canada markets open in 2 hours 3 minutes

Molecular Partners AG (MLLCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.8000-0.3000 (-7.32%)
At close: 11:37AM EDT

Molecular Partners AG

Wagistrasse 14
Schlieren 8952
Switzerland
41 44 755 77 00
https://www.molecularpartners.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees167

Key Executives

NameTitlePayExercisedYear Born
Dr. Patrick Amstutz Ph.D.Co-Founder, CEO, Member of Management Board & Director735.02kN/A1975
Dr. Michael Tobias Stumpp Ph.D.Co-Founder, Executive VP of Projects & Member of Management BoardN/AN/A1972
Mr. Robert HendriksSenior VP of FinanceN/AN/AN/A
Mr. Alexander ZurcherCOO & Member of Management BoardN/AN/A1975
Ms. Renate GloggnerExecutive VP of People & Community and Member of Management BoardN/AN/A1970
Mr. Daniel Steiner Ph.D.Senior Vice President of Research & TechnologyN/AN/AN/A
Mr. Seth D. LewisSenior Vice President of Investor Relations, Communications & StrategyN/AN/AN/A
Mr. Michael PitznerGeneral Counsel, Compliance Officer, Senior VP Legal & Business DevelopmentN/AN/AN/A
Dr. Pamela A. Trail Ph.D.Strategic ConsultantN/AN/A1956
Ms. Anne Goubier D.V.M., Ph.D.Senior Vice President of Research & Early DevelopmentN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Corporate Governance

Molecular Partners AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.